SBIR/STTR Research Award

A new method to express siRNA

Award identifier fdfd182782c495d5dde3efcd6851d2d45abdec66672b6b0ffd84bc1ba67c2ccdAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$132,320

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
AMBION DIAGNOSTICS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Small interfering RNA (siRNA) specifically degrades target complementary mRNAs in cells. The vector system that controls the expression of siRNAs has been widely used for academic research and clinical therapy. Although Pol III promoters are used to express small hairpin RNA to down-regulate genes in mammalian cells, the efficiency is not as potent as once hoped. It is also difficult to determine if cells express siRNA after transfection and it is hard to identify which cells express siRNAs. In this phase I study, we propose a novel Pol II promoter-controlled siRNA expression system. In this system, individual cells expressing siRNA can be traced and visualized by light microscopy. To detect expressing siRNA in cells more efficiently, we have also designed a new acrylamide-gel based isolation system that can enrich siRNAs (or any small RNA molecules) easily, quickly and with high efficiency. The new Pol ll-controlled siRNA expression vector and small RNA enrichment system has been devised and primarily tested. In this Phase I study, we will finally construct and optimize the siRNA expression vector and enrichment system. In phase II of the project, we will expand this new siRNA expression system to degrade specific mRNAs in a tissue- or cell type-specific manner. The specific aims of this Phase I feasibility study are: 1). Develop new Pol II promoter-controlled siRNA expressing vectors to down-regulate mRNA expressions 2). Develop a new small RNA isolation and enrichment system Successful completion of these goals will provide a novel system allowing researchers the ability to easily and verifiably down-regulate the expression of target genes. Furthermore, it will prove the feasibility of this approach and provide a firm foundation for the Phase II development of regulated knockdown strategies that will greatly enhance gene function studies.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.